Zhou Yujing, Liu Xingdang
Department of Nuclear Medicine, Huashan Hospital, Fudan University, No.12 Urumchi Middle Road, Jing'an District, Shanghai, 200040 China.
Biomark Res. 2020 Sep 7;8:39. doi: 10.1186/s40364-020-00223-2. eCollection 2020.
Breast cancer, a malignant tumor originating from mammary epithelial tissue, is the most common cancer among women worldwide. Challenges facing the diagnosis and treatment of breast cancer necessitate the search for new mechanisms and drugs to improve outcomes. Estrogen receptor (ER) is considered to be important for determining the diagnosis and treatment strategy. The discovery of the second estrogen receptor, ERβ, provides an opportunity to understand estrogen action. The emergence of ERβ can be traced back to 1996. Over the past 20 years, an increasing body of evidence has implicated the vital effect of ERβ in breast cancer. Although there is controversy among scholars, ERβ is generally thought to have antiproliferative effects in disease progression. This review summarizes available evidence regarding the involvement of ERβ in the clinical treatment and prognosis of breast cancer and describes signaling pathways associated with ERβ. We hope to highlight the potential of ERβ as a therapeutic target.
乳腺癌是一种起源于乳腺上皮组织的恶性肿瘤，是全球女性中最常见的癌症。乳腺癌诊断和治疗面临的挑战促使人们寻找新的机制和药物来改善治疗效果。雌激素受体（ER）被认为对确定诊断和治疗策略很重要。第二种雌激素受体ERβ的发现为理解雌激素作用提供了契机。ERβ的出现可以追溯到1996年。在过去20年里，越来越多的证据表明ERβ在乳腺癌中具有重要作用。尽管学者们存在争议，但ERβ通常被认为在疾病进展中具有抗增殖作用。本综述总结了关于ERβ参与乳腺癌临床治疗和预后的现有证据，并描述了与ERβ相关的信号通路。我们希望强调ERβ作为治疗靶点的潜力。
